Shire Files Preliminary Injunction Against Roche to Protect Its Intellectual Property

On December 14, 2017, Shire filed a motion for preliminary injunction against Roche subsidiaries Genentech Inc. and Chugai Pharmaceutical Co., Ltd., as part of our ongoing U.S. patent infringement lawsuit to protect our ‘590 patent from infringement by Roche’s emicizumab, currently being marketed as HEMLIBRA.®

Shire remains steadfastly committed to the hemophilia community and cares deeply that patients are treated appropriately. The filing of the preliminary injunction is not a decision we made lightly, and we carefully considered the impact this filing may have on hemophilia patients. Until the court‘s decision on the motion for the preliminary injunction, expected summer 2018, is made there will be no patient impact. Shire has proactively proposed a carve-out provision to facilitate access for patients, but the scope of the provision is ultimately a matter for the court to decide.

Intellectual property protection laws afford Shire, and other companies in the pharmaceutical industry, the ability to reinvest, innovate and provide value to the patient communities they serve. It is for this reason we believe we have a responsibility to rigorously protect our intellectual property.

Shire has a long track record of successfully resolving U.S. patent issues, and after over two years of discussions with Roche, we are optimistic and confident that this intellectual property matter will now have an accelerated resolution.

For media inquiries, please contact Gwen Fisher at gfisher@shire.com or (781) 482-9649.

For investor relations inquiries, please contact Sun Kim at sun.kim@shire.com or (617) 588-8175.

©2017 Shire US Inc., Lexington, MA 02421. All rights reserved. 1-800-828-2088. SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates. All other trademarks are the property of their respective owners.

 

To read more Press Release articles, click here.